How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

被引：190

作者：

Watanabe, Kazutoshi ^{[1
]}

Tanaka, Masahiko ^{[2
]}

Yuki, Satoshi ^{[3
]}

Hirai, Manabu ^{[4
]}

Yamamoto, Yorihiro ^{[2
]}

机构：

[1] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Aoba Ku, 1000 Kamoshida Cho, Yokohama, Kanagawa 2270033, Japan

[2] Tokyo Univ Technol, Sch Biosci & Biotechnol, 1404-1 Katakura Cho, Hachioji, Tokyo 1920982, Japan

[3] Mitsubishi Tanabe Pharma Corp, Lkuyaku Integrated Value Dev Div, Chuo Ku, 17-10 Nihonbashi Koamicho, Tokyo 1038405, Japan

[4] Mitsubishi Tanabe Pharma Corp, Lkuyaku Integrated Value Dev Div, Chuo Ku, 3-2-10 Dosho Machi, Osaka 5418505, Japan

来源：

JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION | 2018年 / 62卷 / 01期

关键词：

edaravone; radical scavenger; antioxidant; acute ischemic stroke; amyotrophic lateral sclerosis; FREE-RADICAL SCAVENGER; CEREBRAL-ARTERY OCCLUSION; PLASMA OXIDIZED LDL; FREE FATTY-ACIDS; LIPID-PEROXIDATION; OXIDATIVE STRESS; ANTIOXIDANT ACTIVITY; IN-VITRO; RAT-BRAIN; VITAMIN-E;

D O I：

10.3164/jcbn.17-62

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

Edaravone is a low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the radical. Thus, it inhibits the oxidation of lipids by scavenging chain-initiating water-soluble peroxyl radicals and chain-carrying lipid peroxyl radicals. In 2001, it was approved in Japan as a drug to treat acute phase cerebral infarction, and then in 2015 it was approved for amyotrophic lateral sclerosis (ALS). In 2017, the U.S. Food and Drug Administration also approved edaravone for treatment of patients with ALS. Its mechanism of action was inferred to be scavenging of peroxynitrite. In this review, we focus on the radical-scavenging characteristics of edaravone in comparison with some other antioxidants that have been studied in clinical trials, and we summarize its pharmacological action and clinical efficacy in patients with acute cerebral infarction and ALS.

引用

页码：20 / 38

页数：19

共 119 条

[1] STRONG ATTENUATION OF ISCHEMIC AND POSTISCHEMIC BRAIN EDEMA IN RATS BY A NOVEL FREE-RADICAL SCAVENGER [J].